Nanexa AB - Home

VISION & MISSION

Nanexa will be a world leading drug development company for Long Acting Injectables, developing a new generation of innovative drug products enabled by our unique PharmaShell® technology”

In its state-of-the-art pilot plant and labs in Uppsala, Nanexa runs the development of own product projects and collaborative projects with other pharmaceutical companies, based on the PharmaShell® system.

PRESSRELEASES

1 October, 2024

All patients in Nanexa Phase 1 study of NEX-22 dosed according to plan

Nanexa AB today announces that dosing of the last patient has been completed in the Phase 1 study of the long-acting depot formulation of the GLP-1 analog liraglutide PharmaShell®.

17 September, 2024

Nanexa starts the final dose group in the Phase 1 study of NEX-22 for treatment of Type 2 Diabetes

Nanexa AB today announces that the first patient in the third dose group with their long-acting depot formulation of the GLP-1 analog liraglutide has been dosed. The study started in Jun 2024 and have so far studied two consecutive dose groups with escalating doses.